Tirdzniecība Annexon, Inc. - ANNX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.05 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Annexon Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 2.71 |
| Atvērt* | 2.73 |
| Izmaiņas par 1 gadu* | -16% |
| Dienas Diapazons* | 2.64 - 3.04 |
| 52 ned Diapazons | 2.07-7.65 |
| Vidējais apjoms (10 dienas) | 2.25M |
| Vidējais apjoms (3 mēneši) | 15.94M |
| Tirgus Kapitalizācija | 151.29M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 53.08M |
| Ieņēmumi | N/A |
| EPS | -2.47 |
| Dividende (Ienesīgums %) | N/A |
| Beta | -100.00K |
| Nākamās Peļņas Datums | Aug 7, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 2.97 | 0.14 | 4.95% | 2.83 | 3.03 | 2.60 |
| May 30, 2023 | 2.71 | 0.02 | 0.74% | 2.69 | 2.95 | 2.48 |
| May 26, 2023 | 2.78 | 0.71 | 34.30% | 2.07 | 2.81 | 2.05 |
| May 25, 2023 | 2.06 | -0.36 | -14.88% | 2.42 | 2.44 | 2.04 |
| May 24, 2023 | 5.15 | -0.33 | -6.02% | 5.48 | 5.63 | 5.05 |
| May 23, 2023 | 5.57 | -0.22 | -3.80% | 5.79 | 6.09 | 5.56 |
| May 22, 2023 | 5.94 | 0.27 | 4.76% | 5.67 | 6.04 | 5.66 |
| May 19, 2023 | 5.86 | 0.13 | 2.27% | 5.73 | 5.97 | 5.67 |
| May 18, 2023 | 5.76 | -0.47 | -7.54% | 6.23 | 6.61 | 5.72 |
| May 17, 2023 | 6.35 | 0.38 | 6.37% | 5.97 | 6.40 | 5.78 |
| May 16, 2023 | 6.00 | 0.06 | 1.01% | 5.94 | 6.15 | 5.77 |
| May 15, 2023 | 6.03 | 0.60 | 11.05% | 5.43 | 6.22 | 5.41 |
| May 12, 2023 | 5.44 | -0.02 | -0.37% | 5.46 | 5.59 | 5.41 |
| May 11, 2023 | 5.45 | -0.15 | -2.68% | 5.60 | 5.67 | 5.38 |
| May 10, 2023 | 5.59 | 0.20 | 3.71% | 5.39 | 5.79 | 5.35 |
| May 9, 2023 | 5.43 | 0.33 | 6.47% | 5.10 | 5.48 | 4.90 |
| May 8, 2023 | 5.21 | 0.17 | 3.37% | 5.04 | 5.26 | 5.03 |
| May 5, 2023 | 5.24 | 0.14 | 2.75% | 5.10 | 5.38 | 5.07 |
| May 4, 2023 | 5.17 | 0.23 | 4.66% | 4.94 | 5.19 | 4.90 |
| May 3, 2023 | 5.06 | 0.36 | 7.66% | 4.70 | 5.15 | 4.66 |
Annexon, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Laiks (UTC) (UTC) 13:30 | Valsts US
| Notikums Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 9, 2023 | ||
| Laiks (UTC) (UTC) 16:00 | Valsts US
| Notikums Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q2 2023 Annexon Inc Earnings Release Q2 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Laiks (UTC) (UTC) 12:30 | Valsts US
| Notikums Q3 2023 Annexon Inc Earnings Release Q3 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | 145.599 | 130.713 | 63.469 | 32.328 | 19.112 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 33.098 | 30.647 | 14.198 | 7.994 | 3.619 |
| Pētniecība un Attīstība | 112.501 | 100.066 | 49.271 | 24.524 | 15.528 |
| Darbības Izdevumi | -145.599 | -130.713 | -63.469 | -32.328 | -19.112 |
| Citi, Neto | 3.652 | 0.385 | 0.048 | -4.865 | 0.769 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -141.947 | -130.323 | -63.412 | -37.179 | -18.303 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Ārkārtas Posteņi Kopā | |||||
| Neto Ienākumi | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Total Adjustments to Net Income | 0 | -6.924 | -1.095 | -0.176 | |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Atšķaidītie Neto Ienākumi | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Atšķaidītie Ienākumi par Akcijām | 54.6736 | 38.3163 | 16.9624 | 187.289 | 187.289 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.59626 | -3.40124 | -4.14658 | -0.20438 | -0.09867 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Atšķaidītā Normalizētā Peļņa par Akciju | -2.59626 | -3.40124 | -4.14658 | -0.20504 | -0.09879 |
| Neparedzēti Izdevumi (Ienākumi) | -0.19 | -0.035 | |||
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.005 | 0.009 | 0.014 | 0.04 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0 | 0 | 0 | 0 | 0 |
| Kopējie Darbības Izdevumi | 41.242 | 36.695 | 36.069 | 37.409 | 35.426 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 8.897 | 8.16 | 8.207 | 8.303 | 8.428 |
| Pētniecība un Attīstība | 32.345 | 28.535 | 27.862 | 29.106 | 26.998 |
| Darbības Izdevumi | -41.242 | -36.695 | -36.069 | -37.409 | -35.426 |
| Citi, Neto | 2.566 | 2.312 | 1.015 | 0.272 | 0.053 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Neto Ienākumi | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Total Adjustments to Net Income | |||||
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Atšķaidītie Neto Ienākumi | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Atšķaidītie Ienākumi par Akcijām | 73.8556 | 72.563 | 68.6529 | 38.5844 | 38.5634 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 248.098 | 247.693 | 354.011 | 45.406 | 45.706 |
| Nauda un Īstermiņa Ieguldījumi | 242.657 | 242.715 | 351.206 | 43.931 | 44.175 |
| Nauda un Ekvivalenti | 140.02 | 74.843 | 268.565 | 43.931 | 44.175 |
| Prepaid Expenses | 5.238 | 4.515 | 2.802 | 1.396 | 1.306 |
| Total Assets | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Property/Plant/Equipment, Total - Net | 35.966 | 38.181 | 1.935 | 2.138 | 2.345 |
| Property/Plant/Equipment, Total - Gross | 38.849 | 38.97 | 3.906 | 3.442 | 3.156 |
| Accumulated Depreciation, Total | -2.883 | -0.789 | -1.971 | -1.304 | -0.811 |
| Other Long Term Assets, Total | 1.032 | 1.166 | 0 | 2.354 | 0.098 |
| Total Current Liabilities | 22.36 | 21.744 | 10.622 | 4.931 | 3.326 |
| Accounts Payable | 7.416 | 11.153 | 3.734 | 2.371 | 1.271 |
| Accrued Expenses | 14.764 | 10.452 | 6.497 | 2.194 | 1.713 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.18 | 0.139 | 0.391 | 0.366 | 0.342 |
| Total Liabilities | 53.902 | 55.131 | 11.668 | 6.368 | 5.129 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 31.542 | 33.387 | 1.046 | 1.437 | 1.803 |
| Total Equity | 231.194 | 231.909 | 344.278 | 43.53 | 43.02 |
| Redeemable Preferred Stock | 0 | 0 | 143.984 | 107.222 | |
| Common Stock | 0.048 | 0.039 | 0.038 | 0.004 | 0.004 |
| Additional Paid-In Capital | 669.78 | 528.365 | 510.309 | 2.202 | 1.257 |
| Retained Earnings (Accumulated Deficit) | -438.262 | -296.315 | -165.992 | -102.58 | -65.397 |
| Other Equity, Total | -0.372 | -0.18 | -0.077 | -0.08 | -0.066 |
| Total Liabilities & Shareholders’ Equity | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Total Common Shares Outstanding | 47.723 | 38.5608 | 38.1576 | 187.289 | 187.289 |
| Debitoru Parādu Kopsumma, Neto | 0 | 0.003 | 0.079 | 0.225 | |
| Īstermiņa Ieguldījumi | 102.637 | 167.872 | 82.641 | ||
| Other Current Assets, Total | 0.203 | 0.463 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 232.536 | 248.098 | 274.777 | 181.372 | 211.254 |
| Nauda un Īstermiņa Ieguldījumi | 228.165 | 242.657 | 269.519 | 177.594 | 206.659 |
| Nauda un Ekvivalenti | 144.12 | 140.02 | 210.658 | 104.614 | 112.828 |
| Īstermiņa Ieguldījumi | 84.045 | 102.637 | 58.861 | 72.98 | 93.831 |
| Debitoru Parādu Kopsumma, Neto | |||||
| Prepaid Expenses | 4.206 | 5.238 | 5.201 | 3.741 | 4.461 |
| Total Assets | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Property/Plant/Equipment, Total - Net | 35.198 | 35.966 | 36.709 | 37.282 | 37.908 |
| Accumulated Depreciation, Total | -3.419 | -2.883 | -2.353 | -1.834 | -1.295 |
| Other Long Term Assets, Total | 1.044 | 1.032 | 1.236 | 2.05 | 1.407 |
| Total Current Liabilities | 22.941 | 22.36 | 20.22 | 20.254 | 17.053 |
| Accounts Payable | 10.346 | 7.416 | 6.921 | 10.301 | 9.378 |
| Accrued Expenses | 12.211 | 14.764 | 13.129 | 9.789 | 7.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.384 | 0.18 | 0.17 | 0.164 | 0.189 |
| Total Liabilities | 53.917 | 53.902 | 52.12 | 52.66 | 49.955 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 30.976 | 31.542 | 31.9 | 32.406 | 32.902 |
| Total Equity | 214.861 | 231.194 | 260.602 | 168.044 | 200.614 |
| Common Stock | 0.053 | 0.048 | 0.048 | 0.039 | 0.039 |
| Additional Paid-In Capital | 691.963 | 669.78 | 664.839 | 537.269 | 532.636 |
| Retained Earnings (Accumulated Deficit) | -476.938 | -438.262 | -403.879 | -368.825 | -331.688 |
| Other Equity, Total | -0.217 | -0.372 | -0.406 | -0.439 | -0.373 |
| Total Liabilities & Shareholders’ Equity | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Total Common Shares Outstanding | 53.0807 | 47.723 | 47.6265 | 38.6039 | 38.5636 |
| Property/Plant/Equipment, Total - Gross | 38.617 | 38.849 | 39.062 | 39.116 | 39.203 |
| Other Current Assets, Total | 0.165 | 0.203 | 0.057 | 0.037 | 0.134 |
| Redeemable Preferred Stock |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Nauda no Darbības | -116.309 | -106.11 | -53.087 | -28.358 | -17.19 |
| Nauda no Darbības | 2.106 | 2.141 | 0.667 | 0.493 | 0.488 |
| Bezskaidras Naudas Preces | 19.794 | 18.788 | 4.941 | 7.707 | 0.148 |
| Cash Taxes Paid | 0 | 0.002 | 0.001 | ||
| Izmaiņas Apgrozāmajā Kapitālā | 3.738 | 3.284 | 4.717 | 0.625 | 0.478 |
| Nauda no Ieguldījumu Darbībām | 58.443 | -88.236 | -83.164 | -0.267 | -0.017 |
| Kapitālie Izdevumi | -6.526 | -1.654 | -0.464 | -0.267 | -0.017 |
| Nauda no Darbībām ar Finansēšanu | 122.908 | 1.795 | 360.876 | 28.395 | 58.456 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 130.896 | 1.795 | 363.85 | 30 | 58.456 |
| Ārvalstu Valūtas Ietekme | 0.001 | -0.005 | 0.009 | -0.014 | -0.04 |
| Neto Izmaiņas Naudā | 65.043 | -192.556 | 224.634 | -0.244 | 41.209 |
| Naudas Plūsma Finansēšanas Posteņos | -7.988 | 0 | -2.974 | -1.605 | 0 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 64.969 | -86.582 | -82.7 | ||
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -38.676 | -141.947 | -107.564 | -72.51 | -35.373 |
| Cash From Operating Activities | -32.993 | -116.309 | -89.17 | -58.452 | -30.288 |
| Cash From Operating Activities | 0.536 | 2.106 | 1.576 | 1.058 | 0.518 |
| Non-Cash Items | 3.969 | 19.794 | 14.89 | 9.842 | 4.862 |
| Changes in Working Capital | 1.178 | 3.738 | 1.928 | 3.158 | -0.295 |
| Cash From Investing Activities | 19.517 | 58.443 | 102.058 | 87.96 | 68.251 |
| Capital Expenditures | -0.137 | -6.526 | -6.244 | -6.075 | -5.214 |
| Other Investing Cash Flow Items, Total | 19.654 | 64.969 | 108.302 | 94.035 | 73.465 |
| Cash From Financing Activities | 17.581 | 122.908 | 122.8 | 0.132 | 0.019 |
| Financing Cash Flow Items | -7.988 | -7.853 | |||
| Issuance (Retirement) of Stock, Net | 17.581 | 130.896 | 130.653 | 0.132 | 0.019 |
| Foreign Exchange Effects | -0.005 | 0.001 | -0.007 | -0.003 | 0.003 |
| Net Change in Cash | 4.1 | 65.043 | 135.681 | 29.637 | 37.985 |
| Issuance (Retirement) of Debt, Net |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Satter Management Co., L.P. | Private Equity | 13.2922 | 7056024 | 0 | 2023-03-31 | MED |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 9.2054 | 4886616 | 0 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 6.6875 | 3549975 | 0 | 2023-03-31 | LOW |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.5993 | 3503190 | 0 | 2023-03-31 | LOW |
| VR Adviser, LLC | Venture Capital | 6.066 | 3220050 | 0 | 2023-03-31 | MED |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 5.7603 | 3057800 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 4.5459 | 2413117 | -87190 | 2023-03-31 | HIGH |
| Eventide Asset Management, LLC | Investment Advisor | 3.5175 | 1867250 | -1759258 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9575 | 1569971 | 21100 | 2023-03-31 | LOW |
| GMT Capital Corp. | Hedge Fund | 2.6537 | 1408697 | 1408697 | 2023-03-31 | MED |
| Millennium Management LLC | Hedge Fund | 2.5702 | 1364343 | 837812 | 2023-03-31 | HIGH |
| Cormorant Asset Management, LP | Hedge Fund | 2.3548 | 1250000 | 1250000 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.3222 | 1232713 | 0 | 2023-03-31 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 2.2417 | 1190000 | 1190000 | 2023-03-31 | MED |
| Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 2.0552 | 1090986 | -200586 | 2023-03-31 | MED |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.9183 | 1018303 | 1018303 | 2023-03-31 | LOW |
| Polar Capital LLP | Investment Advisor/Hedge Fund | 1.8838 | 1000000 | 1000000 | 2023-03-31 | LOW |
| Soleus Capital Management, L.P. | Hedge Fund | 1.7244 | 915400 | 915400 | 2023-03-31 | HIGH |
| Novartis AG | Corporation | 1.7157 | 910747 | -1196497 | 2021-12-31 | LOW |
| Clarus Ventures, LLC | Venture Capital | 1.7147 | 910211 | 0 | 2023-03-31 |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group530K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$46M+
Ikmēneša ieguldījumu apjoms
$31M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Annexon, Inc. Company profile
Par Annexon, Inc.
Annexon, Inc. ir klīniskās stadijas biofarmācijas uzņēmums, kas izstrādā terapiju pacientiem ar klasiskām komplementa mediētām ķermeņa, smadzeņu un acu slimībām. Uzņēmuma kandidātprodukts ANX005 ir pilna garuma monoklonāla antiviela, kas izstrādāta intravenozai ievadīšanai autoimūnu un neirodeģeneratīvu traucējumu gadījumā. Uzņēmuma kandidātprodukts ANX007 ir antigēnu saistošs fragments (Fab), kas paredzēts intravitreālai ievadīšanai neirodeģeneratīvu oftalmoloģisko traucējumu ārstēšanai. Uzņēmums izstrādā arī ANX009, kas ir pētniecisks Fab preparāts, kas paredzēts sistēmisku autoimūnu slimību ārstēšanai. Uzņēmums ir pabeidzis 1.b fāzes klīniskos pētījumus par ANX005 un ANX007 drošumu un devas noteikšanu pacientiem attiecīgi ar Gijēna-Barē sindromu (GBS) un glaukomu. Uzņēmums veic arī klīniskos pētījumus ar vairākām nopietnām autoimūnām, neirodeģeneratīvām un oftalmoloģiskām slimībām.
| Industry: | Biopharmaceuticals |
1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 530 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com